Met Life Investment Management, LLC Replimune Group, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 35,134 shares of REPL stock, worth $439,175. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,134
Previous 28,918 21.5%
Holding current value
$439,175
Previous $260,000 48.08%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$8.09 - $11.23 $50,287 - $69,805
6,216 Added 21.5%
35,134 $385,000
Q2 2024

Aug 13, 2024
BUY
$5.01 - $9.46 $11,387 - $21,502
2,273 Added 8.53%
28,918 $260,000
Q1 2024

May 14, 2024
BUY
$6.87 - $9.31 $183,051 - $248,064
26,645 New
26,645 $217,000
Q4 2023

Feb 14, 2024
BUY
$6.75 - $16.18 $34,695 - $83,165
5,140 Added 23.9%
26,645 $224,000
Q3 2023

May 09, 2024
SELL
$15.96 - $22.18 $48,981 - $68,070
-3,069 Reduced 12.49%
21,505 $367,000
Q2 2023

Apr 29, 2024
BUY
$15.65 - $24.1 $336,553 - $518,270
21,505 New
21,505 $499,000
Q2 2023

Aug 10, 2023
SELL
$15.65 - $24.1 $48,029 - $73,962
-3,069 Reduced 12.49%
21,505 $499,000
Q1 2023

May 09, 2024
BUY
$17.48 - $29.09 $429,553 - $714,857
24,574 New
24,574 $434 Million
Q1 2023

May 15, 2023
BUY
$17.48 - $29.09 $51,531 - $85,757
2,948 Added 13.63%
24,574 $433,000
Q4 2022

Jun 14, 2023
SELL
$17.09 - $27.91 $50,381 - $82,278
-2,948 Reduced 12.0%
21,626 $588,000
Q3 2022

May 10, 2024
BUY
$15.6 - $21.15 $100,105 - $135,719
6,417 Added 42.19%
21,626 $373,000
Q3 2022

Jun 14, 2023
SELL
$15.6 - $21.15 $45,988 - $62,350
-2,948 Reduced 12.0%
21,626 $373,000
Q3 2022

Mar 22, 2023
BUY
$15.6 - $21.15 $100,105 - $135,719
6,417 Added 42.19%
21,626 $373,000
Q3 2022

Nov 14, 2022
BUY
$15.6 - $21.15 $100,105 - $135,719
6,417 Added 42.19%
21,626 $373,000
Q2 2022

Jun 20, 2023
SELL
$13.32 - $19.98 $124,741 - $187,112
-9,365 Reduced 38.11%
15,209 $265,000
Q1 2022

May 10, 2024
BUY
$15.24 - $29.75 $231,785 - $452,467
15,209 New
15,209 $258,000
Q1 2022

Jun 20, 2023
SELL
$15.24 - $29.75 $142,722 - $278,608
-9,365 Reduced 38.11%
15,209 $258,000
Q1 2022

Mar 22, 2023
BUY
$15.24 - $29.75 $81,442 - $158,984
5,344 Added 54.17%
15,209 $258,000
Q1 2022

May 12, 2022
BUY
$15.24 - $29.75 $81,442 - $158,984
5,344 Added 54.17%
15,209 $258,000
Q4 2021

Jun 21, 2023
SELL
$25.43 - $34.25 $374,049 - $503,783
-14,709 Reduced 59.86%
9,865 $267,000
Q3 2021

Jun 21, 2023
SELL
$28.98 - $39.54 $426,266 - $581,593
-14,709 Reduced 59.86%
9,865 $292,000
Q2 2021

Jun 21, 2023
SELL
$28.5 - $39.37 $419,206 - $579,093
-14,709 Reduced 59.86%
9,865 $379,000
Q1 2021

May 17, 2024
SELL
$30.22 - $45.57 $507,091 - $764,664
-16,780 Reduced 62.98%
9,865 $300,000
Q1 2021

Jun 26, 2023
SELL
$30.22 - $45.57 $444,505 - $670,289
-14,709 Reduced 59.86%
9,865 $301 Million
Q4 2020

Jun 22, 2023
SELL
$23.5 - $52.65 $345,661 - $774,428
-14,709 Reduced 59.86%
9,865 $376,000
Q3 2020

Jun 26, 2023
SELL
$18.85 - $27.0 $277,264 - $397,143
-14,709 Reduced 59.86%
9,865 $227,000
Q2 2020

May 24, 2024
SELL
$9.76 - $25.95 $163,772 - $435,441
-16,780 Reduced 62.98%
9,865 $245 Million
Q2 2020

Jun 26, 2023
SELL
$9.76 - $25.95 $143,559 - $381,698
-14,709 Reduced 59.86%
9,865 $245,000
Q2 2020

Mar 22, 2023
SELL
$9.76 - $25.95 $114,787 - $305,197
-11,761 Reduced 54.38%
9,865 $245,000
Q2 2020

Aug 14, 2020
BUY
$9.76 - $25.95 $96,282 - $255,996
9,865 New
9,865 $245,000

Others Institutions Holding REPL

# of Institutions
149
Shares Held
68M
Call Options Held
52.3K
Put Options Held
80.3K
View Full List

About Replimune Group, Inc.

REPL Quotes by TradingView
  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email